CRMD Stock Analysis: Buy, Sell, or Hold?
CRMD - CorMedix Inc.
$6.86
0.15 (2.24%)
▲
5d:
+6.85%
30d:
-3.79%
90d:
-45.25%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 05, 2026
Smart Money Accumulation
CRMD is down 4.8% this week, but smart money is accumulating calls. Top strike: $9 2026-05-15 with 1,797 OI. Call ratio: 82% View Scanner →
Strength: 5.6/10
Get Alerted When CRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CRMD shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CRMD shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.81
Based on -2.7% avg growth
INTRINSIC VALUE TODAY
$2.36
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CRMD is currently trading at $6.86, which is considered fair relative to its 30-day fair value range of $6.42 to $7.10. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.2) compared to its historical average (6.0). At these levels, the market is pricing in 15.4% annual earnings growth.
Technical Outlook: Technically, CRMD is in a strong downtrend. The price is approaching resistance at $6.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRMD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.57 (+117.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRMD is in a strong downtrend. The price is approaching resistance at $6.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRMD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.57 (+117.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$6.42 -
$7.10
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.7%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 117.2% below Wall St target ($14.57)
- BULLISH: Expecting earnings turnaround to 15.4% growth with 312.1% revenue growth
Fair Price Analysis
30-Day Fair Range
$6.42 -
$7.10
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$6.16
Resistance Level
$6.96
Current Trend
Strong Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.19
Wall Street Target
$14.57
(+117.2%)
Revenue Growth (YoY)
312.1%
Earnings Growth (YoY)
-28.3%
Profit Margin
52.3%
Valuation Premium vs History
+15.4% premium
PE vs Historical
9.2 vs 6.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+15.4%
(market-implied from PE analysis)
1-Year Target
$7.74
(+15%)
2-Year Target
$8.94
(+33%)
3-Year Target
$10.31
(+54%)
3-Yr Target (if PE normalizes)
(PE: 9→6)
PE COMPRESSION
$6.73
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: -9.3%)
$12.19
(+82%)
Base:
(SPY PE: 9.2, Growth: -9.3%)
$5.00
(-25%)
Bear:
(PE: 6.0, Growth: -9.3%)
$3.27
(-51%)
📈
Valuation based on Current Earnings
Trailing PE: 3.06 | Current EPS (TTM): $2.04
Bull Case
$3.44
(-47%)
Analyst growth -50.0%, PE expands to 3.4
Base Case
$3.12
(-51%)
Market implied -50.0%, PE stable at 3.1
Bear Case
$4.25
(-34%)
Severe decline -20.0%, PE contracts to 2.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: March 30, 2026 10:27 AM ET
Data refreshes hourly during market hours. Next update: 11:27 AM
Data refreshes hourly during market hours. Next update: 11:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRMD showing a specific setup today?
Insider Activity (6 Months)
1
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Alan W Dunton
SELL
20000 shares
2025-12-30
Joseph Todisco
SELL
30000 shares
2025-12-18
Steven W Lefkowitz
SELL
40000 shares
2025-12-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 63 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 65 BUY |
Advanced CRMD Option Strategies
Professional options setups generated by AI based on today's CRMD price and gamma walls.
